AI BIOTECH WEEKLY · 014 · 2026.11.11
AbCellera Adds Clinical and Funding Evidence as Schrödinger Adds Commercial Proof
AI Biotech Weekly | Issue 014 | 11 November 2026
Clinical and commercial evidence around AI discovery platforms broadened, but dilution, milestone volatility, net losses and replication risk prevent an automatic score increase.
Public research | Full access
This is a broader evidence base, not a jump in success probability. AbCellera adds clinical and funding proof; Schrödinger adds software and milestone-revenue proof. The score stays at 96.
The one-minute brief
AbCellera plans later-stage work for ABCL635 in 2027 and raised roughly $200m of equity, lifting available liquidity to about $890m. Schrödinger reported 17% ACV growth, 49% hosted-software revenue growth and raised guidance. Net losses, milestone volatility, fewer partner programmes and dilution remain open.
Audio transcript
AbCellera and Schrödinger move the AI drug-discovery evidence chain forward without closing the bridge to investor cash returns. ABCL635 continues toward later-stage development and AbCellera has about 890 million dollars of available liquidity after financing. Yet partner programmes fell from 44 to 34 and shares increased 8.6 percent. Schrödinger's ACV grew 17 percent and hosted revenue grew 49 percent, while software gross margin fell two points and net loss was 37.7 million dollars. The score remains 96.
01 · SCORE & MEASUREMENT
Evidence maturity, not expected return
The 0–100 score measures evidence maturity, not drug-success probability, expected return or a buy signal. Clinical, commercial, cash and investor-return evidence are assessed separately.
| Module | Prior | Current | Change / Read |
|---|---|---|---|
| AI Biotech | 96 | 96 | 0 / High |
| Earnings Intelligence | L3 | L3 | Human Review |
| Broad FOMO | UNKNOWN | UNKNOWN | Not comparable / Low |
| AI Crowding | UNKNOWN | UNKNOWN | Not comparable / Low |
| Market Breadth | UNKNOWN | UNKNOWN | Not comparable / Low |
| Four-quadrant regime | UNKNOWN | UNKNOWN | Not comparable / Low |
02 · WHAT CHANGED
Evidence before narrative
AbCellera's clinical boundary
ABCL635 Phase 2 top-line results were first disclosed in August. This week's additions are cash, financing, pipeline and development decisions. Later-stage work is planned for 2027, but full data, regulatory dialogue, trial design and replication remain necessary.
A signal is not a capital-allocation decision
ABCL575 reached its Phase 1 endpoint, but the company does not plan to continue development. A clinical endpoint, strategic priority, economic rights and commercial value are different questions.
Fewer partner programmes
Partner programmes fell from 44 at the end of 2025 to 34, with 12 clinical molecules. Liquidity cannot obscure that decline; each termination, de-duplication, right and potential economic contribution needs review.
AbCellera cash and dilution
Q3 revenue was $10.6m and net loss was $40.8m. Nine-month operating cash flow was $19.3m, including a $66.1m increase in deferred revenue. Cash and securities were $764.4m; shares rose 8.6% from 300.6m to 326.3m. Financing improves survival, not revenue or free cash flow.
Schrödinger commercialisation
ACV was $44.7m, up 17%; software revenue was $38.2m, up 6%; hosted-software revenue was $17.2m, up 49% and 45% of software revenue. Paid use and migration are stronger, but recognised revenue still trails contract value.
Margin and milestone volatility
Software gross margin was 75%, down 2 points. Drug-discovery revenue of $24.2m included a Structure milestone. Total revenue was $64.5m, up 19%, and net loss was $37.7m. Milestones are non-linear and should not be annualised like subscriptions.
The value-capture chain
Models and physics, software subscriptions and hosting, discovery milestones, clinical and regulatory validation, royalties or product revenue, profit, operating cash flow and free cash flow must be tested in sequence. Financing and partnership counts cannot fill a missing link.
Historical continuity
Recursion and Tempus reuse evidence registered on 4 November and are not double-counted. Absci had not reported Q3 by the evidence cutoff, so current values remain UNKNOWN.
Scenarios and counter-evidence
The bull case requires complete ABCL635 data, strong hosted-software growth and better cash quality. The base case keeps clinical and commercial progress but also losses, dilution and milestone volatility. Bear and tail cases include failed replication, further programme attrition, weaker margins or cash, and safety, regulatory or financing shocks.
Next proof
Validate complete ABCL635 Phase 2 data, regulatory dialogue and later-stage design; programme-level reasons for 44 to 34; post-financing fully diluted shares; Schrödinger ACV, renewals, hosted margin and cash; and Absci's official results.
03 · THESIS → EVIDENCE → UPDATE
What the new evidence changes
Prior view
Recursion added early human efficacy evidence and Tempus added revenue proof, but sample size, cash and investor-return gaps remained.
New evidence
AbCellera adds clinical, cash and funding evidence; Schrödinger adds ACV, hosted-revenue and milestone evidence.
Updated view
The evidence base broadens without closing success-probability, sustained-cash or dilution-adjusted return gaps. The score stays at 96 and Earnings Intelligence remains L3 Human Review.
04 · NEXT VALIDATION
7D / 30D / 90D
| Window | What to validate |
|---|---|
| 24 hours | Check AbCellera financing, pre-funded warrants, shares and pipeline definitions. |
| 7 days | Track complete ABCL635 data, regulatory dialogue, partner-programme changes, and Schrödinger renewals and hosted margin. |
| 30 days | Test post-financing cash burn, dilution, milestone repeatability and the bridge from software revenue to operating cash flow. |
FAQ
Questions readers should ask
Are the Phase 2 top-line results new this week?
No. They were first disclosed in August. This week's additions are cash, financing, pipeline and development decisions.
Does more liquidity mean the business is profitable?
No. Equity financing adds cash and shares. Revenue, profit and sustained free cash flow still require separate proof.
Can milestone revenue be treated like recurring software revenue?
No. Milestones are event-dependent and non-linear, unlike subscriptions or hosted revenue.
Does this automatically change investment status?
No. Weekly owns Evidence; Investment Intelligence owns Decision State, and every real action requires human approval.
KEY TERMS
Reader reference
- Phase 2
- A clinical stage generally used to assess efficacy, dose and safety; top-line data are not a full regulatory conclusion.
- ACV
- Annual contract value, which is not the same as current recognised revenue or cash.
- Milestone revenue
- Revenue recognised when a collaboration reaches a specified event; it can be highly volatile.
- Fully diluted
- A share count that includes potential dilution from options, warrants and pre-funded warrants.
SOURCES & CONTINUITY
Verifiable sources
AbCellera | Q3 2026 business results | 9 Nov 2026 ↗
AbCellera | Q3 2026 Form 10-Q ↗
AbCellera | Q3 2026 business update ↗
Continue reading
Public-source research, not medical or investment advice. Discovery, clinical stage, regulatory approval, scaled commercialisation, recognised revenue and sustained free cash flow are distinct stages. Every real investment or client action requires human approval.